Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues
License revenue	$ 5,025	$ 4,355	$ 1,055
License revenue from related party	2,000	220	2,700
Reagent sales	257	326	368
Grant revenue	306	1,219	1,964
Total revenues	7,588	6,120	6,087
Costs of revenues
Licensing costs (including amounts to related parties)	1,405	885	151
Costs of reagent sales (including amounts to related parties)	98	122	173
Research and development (including amounts to related parties)	17,279	4,961	5,051
General and administrative (including amounts to related parties)	11,912	3,851	5,474
Foreign currency transaction losses	57	30	14
Other operating income	(26)	(47)
Total operating expenses	30,725	9,802	10,863
Loss from operations	(23,137)	(3,682)	(4,776)
Other Income (Expense)
Investment income	346
Interest expense	(20)	(321)	(611)
Total other income (expense)	326	(321)	(611)
Net loss	(22,811)	(4,003)	(5,387)
Other Comprehensive Loss
Unrealized loss on available-for-sale securities	(719)
Total other comprehensive loss	(719)
Comprehensive loss	(23,530)	(4,003)	(5,387)
Reconciliation of net loss to net loss applicable to common stockholders
Net loss	(22,811)	(4,003)	(5,387)
Accretion and dividends on convertible preferred stock	(1,747)	(815)	(422)
Net gain on extinguishment of convertible preferred stock	759
Net loss applicable to common stockholders	$ (23,799)	$ (4,818)	$ (5,809)
Basic and diluted net loss per common share	$ (2.59)	$ (1.82)	$ (2.50)
Weighted-average basic and diluted common shares	9,173	2,643	2,320